S. Loibl

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

S. Loibl, Ian J. Majewski, Valentina Guarneri et al. · Annals of Oncology · 2016 · 228 citations · Full text

Medicine, Molecular Medicine, Oncology +13

Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

Giuseppe Curigliano, Harold J. Burstein, Michael Gnant et al. · Annals of Oncology · 2023 · 221 citations · Full text

Medicine, Oncology, Surgery +17

Surgery for Recurrent Ovarian Cancer: Role of Peritoneal Carcinomatosis: Exploratory Analysis of the DESKTOP I Trial About Risk Factors, Surgical Implications, and Prognostic Value of Peritoneal Carcinomatosis

P Harter, Maik Hahmann, Hans-Joachim Lueck et al. · Annals of Surgical Oncology · 2009 · 136 citations

Medicine, Oncology, Surgery +17

13th St. Gallen International Breast Cancer Conference 2013: Primary Therapy of Early Breast Cancer Evidence, Controversies, Consensus - Opinion of a German Team of Experts (Zurich 2013)

M. Untch, Bernd Gerber, Nadia Harbeck et al. · Breast Care · 2013 · 132 citations · Full text

Medicine, Oncology, Breast Oncology +12

Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum–taxane based therapy—A phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)☆

U WAGNER, Andreas duBois, J. Pfisterer et al. · Gynecologic Oncology · 2006 · 89 citations

Medicine, Oncology, Pharmacology +17